Oxidation of LDL and its clinical implication

Eiji Matsuura, Graham R V Hughes, Munther A. Khamashta

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and apolipoprotein B (apoB) components by lipid peroxidation. This promotes atherosclerosis through inflammatory and immunologic mechanisms that lead to the formation of macrophage foam cells. Recent findings also suggest that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) within atherosclerotic lesions and that these complexes appear in the circulation. Autoantibodies (auto-Abs) against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). These autoantibodies significantly correlate with arterial thrombosis. IgG auto-Abs having similar specificity emerge spontaneously in NZW × BXSB F1 mice, which generally are considered to be an animal model of APS, and these mice produce a monoclonal IgG auto-Ab (WB-CAL-1) against oxLDL/β2GPI complexes. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages, which suggests that such IgG auto-Abs are pro-atherogenic. In contrast, IgM anti-oxLDL natural Abs found in the atherosclerosis-prone mice have been proposed to be protective. The presence of such Abs in humans has been documented in many publications but their exact pathophysiological significance remains unclear. In this article, we review recent progress in our understanding of the clinical significance of oxidation of LDL, formation of oxLDL complexes, and Abs in atherosclerotic and/or autoimmune disease.

Original languageEnglish
Pages (from-to)558-566
Number of pages9
JournalAutoimmunity Reviews
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

LDL Lipoproteins
Glycoproteins
Atherosclerosis
Antiphospholipid Syndrome
Immunoglobulin G
Autoantibodies
Macrophages
Foam Cells
Apolipoproteins B
oxidized low density lipoprotein
Systemic Lupus Erythematosus
C-Reactive Protein
Lipid Peroxidation
Autoimmune Diseases
Publications
Thrombosis
Animal Models
Lipids

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Oxidation of LDL and its clinical implication. / Matsuura, Eiji; Hughes, Graham R V; Khamashta, Munther A.

In: Autoimmunity Reviews, Vol. 7, No. 7, 07.2008, p. 558-566.

Research output: Contribution to journalArticle

Matsuura, Eiji ; Hughes, Graham R V ; Khamashta, Munther A. / Oxidation of LDL and its clinical implication. In: Autoimmunity Reviews. 2008 ; Vol. 7, No. 7. pp. 558-566.
@article{dbc53b86085344a3ac62bc77290ed06a,
title = "Oxidation of LDL and its clinical implication",
abstract = "Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and apolipoprotein B (apoB) components by lipid peroxidation. This promotes atherosclerosis through inflammatory and immunologic mechanisms that lead to the formation of macrophage foam cells. Recent findings also suggest that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) within atherosclerotic lesions and that these complexes appear in the circulation. Autoantibodies (auto-Abs) against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). These autoantibodies significantly correlate with arterial thrombosis. IgG auto-Abs having similar specificity emerge spontaneously in NZW × BXSB F1 mice, which generally are considered to be an animal model of APS, and these mice produce a monoclonal IgG auto-Ab (WB-CAL-1) against oxLDL/β2GPI complexes. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages, which suggests that such IgG auto-Abs are pro-atherogenic. In contrast, IgM anti-oxLDL natural Abs found in the atherosclerosis-prone mice have been proposed to be protective. The presence of such Abs in humans has been documented in many publications but their exact pathophysiological significance remains unclear. In this article, we review recent progress in our understanding of the clinical significance of oxidation of LDL, formation of oxLDL complexes, and Abs in atherosclerotic and/or autoimmune disease.",
author = "Eiji Matsuura and Hughes, {Graham R V} and Khamashta, {Munther A.}",
year = "2008",
month = "7",
doi = "10.1016/j.autrev.2008.04.018",
language = "English",
volume = "7",
pages = "558--566",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Oxidation of LDL and its clinical implication

AU - Matsuura, Eiji

AU - Hughes, Graham R V

AU - Khamashta, Munther A.

PY - 2008/7

Y1 - 2008/7

N2 - Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and apolipoprotein B (apoB) components by lipid peroxidation. This promotes atherosclerosis through inflammatory and immunologic mechanisms that lead to the formation of macrophage foam cells. Recent findings also suggest that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) within atherosclerotic lesions and that these complexes appear in the circulation. Autoantibodies (auto-Abs) against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). These autoantibodies significantly correlate with arterial thrombosis. IgG auto-Abs having similar specificity emerge spontaneously in NZW × BXSB F1 mice, which generally are considered to be an animal model of APS, and these mice produce a monoclonal IgG auto-Ab (WB-CAL-1) against oxLDL/β2GPI complexes. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages, which suggests that such IgG auto-Abs are pro-atherogenic. In contrast, IgM anti-oxLDL natural Abs found in the atherosclerosis-prone mice have been proposed to be protective. The presence of such Abs in humans has been documented in many publications but their exact pathophysiological significance remains unclear. In this article, we review recent progress in our understanding of the clinical significance of oxidation of LDL, formation of oxLDL complexes, and Abs in atherosclerotic and/or autoimmune disease.

AB - Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and apolipoprotein B (apoB) components by lipid peroxidation. This promotes atherosclerosis through inflammatory and immunologic mechanisms that lead to the formation of macrophage foam cells. Recent findings also suggest that oxLDL forms complexes with β2-glycoprotein I (β2GPI) and/or C-reactive protein (CRP) within atherosclerotic lesions and that these complexes appear in the circulation. Autoantibodies (auto-Abs) against oxLDL/β2GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). These autoantibodies significantly correlate with arterial thrombosis. IgG auto-Abs having similar specificity emerge spontaneously in NZW × BXSB F1 mice, which generally are considered to be an animal model of APS, and these mice produce a monoclonal IgG auto-Ab (WB-CAL-1) against oxLDL/β2GPI complexes. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/β2GPI complexes by macrophages, which suggests that such IgG auto-Abs are pro-atherogenic. In contrast, IgM anti-oxLDL natural Abs found in the atherosclerosis-prone mice have been proposed to be protective. The presence of such Abs in humans has been documented in many publications but their exact pathophysiological significance remains unclear. In this article, we review recent progress in our understanding of the clinical significance of oxidation of LDL, formation of oxLDL complexes, and Abs in atherosclerotic and/or autoimmune disease.

UR - http://www.scopus.com/inward/record.url?scp=50949112988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949112988&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2008.04.018

DO - 10.1016/j.autrev.2008.04.018

M3 - Article

C2 - 18625445

AN - SCOPUS:50949112988

VL - 7

SP - 558

EP - 566

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 7

ER -